[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552799":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":32,"responsibleParty":298,"collaborators":300,"id":304,"slug":10,"hasResults":305,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":305,"sex":311,"minAge":312,"maxAge":10,"enrollmentInfo":313,"targetDuration":10,"studyType":316,"phases":10,"briefSummary":317,"conditions":318,"keywords":321,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":334},{"fullName":5,"class":6},"Universitaire Ziekenhuizen KU Leuven","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Relapsed or refractory multiple myeloma patients",null,"Patients aged 18 years or older diagnosed with relapsed or refractory multiple myeloma, who received at least 3 prior lines of treatment. They should be refractory to at least 1 proteasome inhibitor, at least 1 immunomodulatory agent, and an anti-CD38 monoclonal antibody. After confirmation of disease progression, the patients will start treatment with teclistamab per routine clinical care or will have started with teclistamab treatment ≤14 days before intended screening visit",[13],"Drug: Teclistamab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Teclistamab","Intervention is part of standard clinical care, as Tecvayli\u002FTeclistamab is reimbursed for this group of patients.",[9],[21],"Tecvayli",[23],{"name":24,"affiliation":25,"role":26},"Michel Delforge, MD, PhD","UZ Leuven Gasthuisberg","PRINCIPAL_INVESTIGATOR",[28],{"name":24,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","+32 16 34 68 80","michel.delforge@uzleuven.be",[33,53,70,87,103,119,136,152,160,177,194,205,221,238,251,268,284],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Imelda","NOT_YET_RECRUITING","Bonheiden","Antwerpen","2820","Belgium",{"type":41,"coordinates":42},"Point",[43,44],4.54714,51.02261,{"lat":44,"lon":43},[47,51],{"name":48,"role":29,"phone":49,"phoneExt":10,"email":50},"Ann Pauwels","+32 15 50 46 25","sec@imelda.be",{"name":52,"role":26,"phone":10,"phoneExt":10,"email":10},"Helena Maes, MD",{"facility":54,"status":55,"city":56,"state":37,"zip":57,"country":39,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Universitair Ziekenhuis Antwerpen (UZA)","RECRUITING","Edegem","2500",{"type":41,"coordinates":59},[60,61],4.44504,51.15662,{"lat":61,"lon":60},[64,68],{"name":65,"role":29,"phone":66,"phoneExt":10,"email":67},"Anouk Smits","+32 38 21 53 98","studies.hematologie@uza.be",{"name":69,"role":26,"phone":10,"phoneExt":10,"email":10},"Ann Van de Velde, MD, PhD",{"facility":71,"status":55,"city":72,"state":73,"zip":74,"country":39,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Grand Hôpital de Charleroi","Charleroi","Henegouwen","6000",{"type":41,"coordinates":76},[77,78],4.44448,50.41136,{"lat":78,"lon":77},[81,85],{"name":82,"role":29,"phone":83,"phoneExt":10,"email":84},"Christy Vanderperren","+32 71 10 47 60","christy.VANDERPERREN@ghdc.be",{"name":86,"role":26,"phone":10,"phoneExt":10,"email":10},"Géraldine Verstraete, MD",{"facility":88,"status":55,"city":89,"state":73,"zip":90,"country":39,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"EpiCURA","Hornu","7301",{"type":41,"coordinates":92},[93,94],3.82736,50.4328,{"lat":94,"lon":93},[97,101],{"name":98,"role":29,"phone":99,"phoneExt":10,"email":100},"Sophie Viart","+32 65 61 44 89","sophie.viart@epicura.be",{"name":102,"role":26,"phone":10,"phoneExt":10,"email":10},"Géraldine Claes, MD",{"facility":104,"status":55,"city":105,"state":73,"zip":106,"country":39,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"CHU Ambroise Paré","Mons","7000",{"type":41,"coordinates":108},[109,110],3.95229,50.45413,{"lat":110,"lon":109},[113,117],{"name":114,"role":29,"phone":115,"phoneExt":10,"email":116},"Recherche Clinique","+32 65 41 75 01","recherche.clinique@helora.be",{"name":118,"role":26,"phone":10,"phoneExt":10,"email":10},"Caroline Jacquy, MD, PhD",{"facility":120,"status":55,"city":121,"state":122,"zip":123,"country":39,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Jessa Ziekenhuis","Hasselt","Limburg","3500",{"type":41,"coordinates":125},[126,127],5.33781,50.93106,{"lat":127,"lon":126},[130,134],{"name":131,"role":29,"phone":132,"phoneExt":10,"email":133},"Elke Van Campenhout","+32 11 33 79 94","elke.vancampenhout@jessazh.be",{"name":135,"role":26,"phone":10,"phoneExt":10,"email":10},"Koen Theunissen, MD",{"facility":137,"status":55,"city":138,"state":138,"zip":139,"country":39,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"CHR Citadelle","Liège","4000",{"type":41,"coordinates":141},[142,143],5.56749,50.63373,{"lat":143,"lon":142},[146,150],{"name":147,"role":29,"phone":148,"phoneExt":10,"email":149},"Sophie Ledant","+32 43 21 83 51","sophie.ledant@citadelle.be",{"name":151,"role":26,"phone":10,"phoneExt":10,"email":10},"Michelle Pirotte, MD",{"facility":153,"status":55,"city":138,"state":138,"zip":139,"country":39,"cosmosGeoPoint":154,"geoPoint":156,"contacts":157},"CHU Liège",{"type":41,"coordinates":155},[142,143],{"lat":143,"lon":142},[158,159],{"name":147,"role":29,"phone":148,"phoneExt":10,"email":149},{"name":151,"role":26,"phone":10,"phoneExt":10,"email":10},{"facility":161,"status":55,"city":162,"state":163,"zip":164,"country":39,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"CHU UCL Namur","Yvoir","Namur","5530",{"type":41,"coordinates":166},[167,168],4.88059,50.3279,{"lat":168,"lon":167},[171,175],{"name":172,"role":29,"phone":173,"phoneExt":10,"email":174},"Benoit Martin","+32 81 42 38 38","B.martin@chuuclnamur.uclouvain.be",{"name":176,"role":26,"phone":10,"phoneExt":10,"email":10},"Julien Depaus, MD",{"facility":178,"status":55,"city":179,"state":180,"zip":181,"country":39,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"Algemeen Ziekenhuis Maria Middelares (AZMM)","Ghent","Oost-Vlaanderen","9000",{"type":41,"coordinates":183},[184,185],3.71667,51.05,{"lat":185,"lon":184},[188,192],{"name":189,"role":29,"phone":190,"phoneExt":10,"email":191},"Mieke Van Den Berghe","+32 92 46 95 18","Mieke.VanDenBerghe@mijnziekenhuis.be",{"name":193,"role":26,"phone":10,"phoneExt":10,"email":10},"Veerle Galle, MD",{"facility":195,"status":55,"city":179,"state":180,"zip":181,"country":39,"cosmosGeoPoint":196,"geoPoint":198,"contacts":199},"Universitair Ziekenhuis Gent (UZ Gent)",{"type":41,"coordinates":197},[184,185],{"lat":185,"lon":184},[200,203],{"name":201,"role":29,"phone":10,"phoneExt":10,"email":202},"Studies Hematologie","studies.hematologie@uzgent.be",{"name":204,"role":26,"phone":10,"phoneExt":10,"email":10},"Nicolas Kint, MD, PhD",{"facility":206,"status":55,"city":207,"state":180,"zip":208,"country":39,"cosmosGeoPoint":209,"geoPoint":213,"contacts":214},"Vitaz","Sint-Niklaas","9100",{"type":41,"coordinates":210},[211,212],4.1437,51.16509,{"lat":212,"lon":211},[215,219],{"name":216,"role":29,"phone":217,"phoneExt":10,"email":218},"Isabel de Brabander","+32 37 60 25 73","isabel.debrabander@vitaz.be",{"name":220,"role":26,"phone":10,"phoneExt":10,"email":10},"Isabelle Vande Broek, MD, PhD",{"facility":222,"status":55,"city":223,"state":224,"zip":225,"country":39,"cosmosGeoPoint":226,"geoPoint":230,"contacts":231},"Institut Jules Bordet","Brussels","Vlaams-Brabant","1070",{"type":41,"coordinates":227},[228,229],4.34878,50.85045,{"lat":229,"lon":228},[232,236],{"name":233,"role":29,"phone":234,"phoneExt":10,"email":235},"Bénédicte Vucic","+32 25 41 36 47","benedicte.vucic@hubruxelles.be",{"name":237,"role":26,"phone":10,"phoneExt":10,"email":10},"Marie Vercruyssen, MD",{"facility":239,"status":55,"city":223,"state":224,"zip":240,"country":39,"cosmosGeoPoint":241,"geoPoint":243,"contacts":244},"UCL Saint Luc","1200",{"type":41,"coordinates":242},[228,229],{"lat":229,"lon":228},[245,249],{"name":246,"role":29,"phone":247,"phoneExt":10,"email":248},"Charlene Mouafo","+32 27 64 17 36","charlene.mouafo@saintluc.uclouvain.be",{"name":250,"role":26,"phone":10,"phoneExt":10,"email":10},"Marie-Christiane Vekemans, MD",{"facility":252,"status":55,"city":253,"state":254,"zip":255,"country":39,"cosmosGeoPoint":256,"geoPoint":260,"contacts":261},"AZ Groeninge","Kortrijk","West-Vlaanderen","8500",{"type":41,"coordinates":257},[258,259],3.26487,50.82803,{"lat":259,"lon":258},[262,266],{"name":263,"role":29,"phone":264,"phoneExt":10,"email":265},"Ellen Callens","+32 56 63 39 00","ellen.callens@azgroeninge.be",{"name":267,"role":26,"phone":10,"phoneExt":10,"email":10},"Alexander Salembier, MD",{"facility":269,"status":55,"city":270,"state":254,"zip":271,"country":39,"cosmosGeoPoint":272,"geoPoint":276,"contacts":277},"AZ Delta","Roeselare","8800",{"type":41,"coordinates":273},[274,275],3.12269,50.94653,{"lat":275,"lon":274},[278,282],{"name":279,"role":29,"phone":280,"phoneExt":10,"email":281},"Ruth Demeersseman","+32 51 23 75 60","ruth.demeersseman@azdelta.be",{"name":283,"role":26,"phone":10,"phoneExt":10,"email":10},"Rutger Callens, MD",{"facility":25,"status":55,"city":285,"state":10,"zip":286,"country":39,"cosmosGeoPoint":287,"geoPoint":291,"contacts":292},"Leuven","3000",{"type":41,"coordinates":288},[289,290],4.70093,50.87959,{"lat":290,"lon":289},[293,296],{"name":294,"role":29,"phone":10,"phoneExt":10,"email":295},"Dimitri Vanhaen","dimitri.vanhaen@uzleuven.be",{"name":297,"role":26,"phone":10,"phoneExt":10,"email":10},"Michel Delforge, MD PhD",{"type":299,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[301],{"name":302,"class":303},"Janssen Pharmaceutica","INDUSTRY","100552799",false,"NCT06477783","Study on the Clinical Efficacy of Teclistamab","Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium","TECTONIC","Inclusion Criteria:\n\n* Age 18 years or older\n* Written informed consent\n* Has a diagnosis of relapsed and refractory multiple myeloma\n* Has already received at least three previous treatments\n* Is refractory to at least 1 proteasome inhibitor, at least 1 immunomodulatory agent, and an anti-CD38 monoclonal antibody\n* Evidence of disease progression on the last line of therapy, based on determination of response by the IMWG response criteria\n* Anticipated to start treatment with teclistamab per routine clinical care or has started with teclistamab treatment ≤14 days before intended screening visit\n\nExclusion Criteria:\n\n* Has participated in a teclistamab trial (teclistamab or control arm) or teclistamab Single Patient Request (SPR) program\n* Has started teclistamab treatment \\>14 days before intended screening visit.","ALL","18 Years",{"count":314,"type":315},100,"ESTIMATED","OBSERVATIONAL","The aim of this study is to assess the clinical efficacy and safety of the anti-BCMA\u002FCD3 bispecific antibody teclistamab (Tecvayli®) in a prospective, real-life setting in Belgium.",[319,320],"Multiple Myeloma","Hematologic Diseases",[17,21,322,323,324],"Hematology","Efficacy","Safety","2025-03-11",{"date":327,"type":328},"2025-03-12","ACTUAL",{"date":330,"type":328},"2024-12-01",{"date":332,"type":315},"2027-09",{"name":5,"class":6},17]